What’s New...

**VIIS Staff Updates**
Serenity Rowland is the new VIIS Help Desk/Statistical Analyst for the Division of Immunization. Serenity has an A.F.A. from Cecil College and has been working with the Division of Immunization as a Data Integrity Monitor for the past year.

**Proxy Errors in VIIS**
VIIS has been experiencing slowness each morning, which may present as proxy errors. Our technical team is working to resolve the issue as quickly as possible. If you have any questions or concerns, please notify your regional VIIS Consultant or the VIIS Help Desk at 866-375-9795.

**HPV Champion**
The Office of Sein Win has been selected as a HPV Vaccine Is Cancer Prevention Champion for 2017. Led in partnership by the Centers for Disease Control and Prevention (CDC), Association of American Cancer Institutes, and the American Cancer Society, the HPV Vaccine Is Cancer Prevention Champion Award Program recognizes clinicians, clinics, practices, groups, and health systems that are effectively working to protect their adolescent patients against HPV cancers by achieving high HPV vaccination rates. This year, the award program honored one Champion from each of the 10 U.S. Department of Health and Human Services (HHS) regions. After a rigorous review and data validation process of all submissions, the Office of Sein Win stood out as the Champion from HHS region 3.

**VIIS Registration & Training**
Are you in need of VIIS training or know a provider/school who wants access?

Contact a VIIS Consultant at (804) 864-8055 or viisinfo@vdh.virginia.gov.

To register, please visit the link below: https://www.vdh.virginia.gov/verip

Did You Know?

**New Vaccines Coming Soon To VIIS**
Shingrix®, the new shingles vaccine and HEPLISAV-B™, the new hepatitis B vaccine will be added to the registry in 2018. VIIS users will be able to add the vaccines to patient’s records through the VIIS electronic inventory, historical data entry, or data exchange from their EMR (Electronic Medical Record) system.

**Shingles Vaccine: Shingrix®**
The U.S. Food and Drug Administration (FDA) licensed Shingrix® for adults aged 50 years and older to prevent shingles. On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) voted that Shingrix® is:

1. Recommended for healthy adults aged 50 years and older to prevent shingles and related complications.
2. Recommended for adults who previously received the current shingles vaccine (Zostavax®) to prevent shingles and related complications.
3. The preferred vaccine for preventing shingles and related complications.

**Hepatitis B Vaccine: HEPLISAV-B™**
HEPLISAV-B™ is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist to enhance the immune response. HEPLISAV-B™ is the first and only two-dose vaccine in United States for prevention of Hepatitis B in adults. HEPLISAV-B™ is the first new Hepatitis B vaccine in the United States in more than 25 years. HEPLISAV-B™ is approved for use in adults 18 years of age and older.

To find out more about these and other vaccines, visit the website below:

https://www.cdc.gov/vaccines/hcp/vis/index.html
https://www.cdc.gov/shingles/vaccination.html
http://investors.dynavax.com/releasedetail.cfm?releaseid=1048181

Visit us online at: http://www.vdh.virginia.gov/immunization/viis